Gufic Biosciences Ltd.

•

guficbio.comBSE: 509079NSE: GUFICBIO

Market Cap₹ 4,467 Cr.

Current Price

High / Low₹ 454 / 268

Stock P/E60.7

Book Value₹ 68

Price to Book4.15

Dividend Yield0.02 %

ROCE12.5 %

ROE10.0 %

Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2018 • Pharma: 93.8% • Bulk Drugs: 6.2%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Latest quarter profit grew 86.1% YoY, showing strong momentum
Company generates healthy free cash flow
Company has a consistent dividend-paying track record

CONS

Company has delivered a poor profit growth of 7.4% over past five years
Operating margins have contracted to 12.3% from 17.1%
Though reporting repeated profits, the company pays out little dividend (1.6%)
Growth is decelerating - 3Y profit CAGR (-7.5%) trails the 5Y trend (7.4%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	SUNPHARMA	1899.00	37.67	455633.71	0.84	29012.30	1165.33	152998.80	1004.57	19.11	28.81
2.	DIVISLAB	9100.00	82.59	241576.41	0.33	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4850.00	84.58	184478.41	0.78	566.00	3.28	4921.00	57.32	19.27	33.81
4.	CIPLA	1385.00	33.19	111888.39	0.94	785.55	-39.18	7119.28	4.13	16.00	16.73
5.	ZYDUSLIFE	1121.00	24.78	111820.18	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
6.	LAURUSLABS	1840.00	90.93	99417.45	0.11	362.07	123.94	2026.31	29.10	18.20	31.50
7.	LUPIN	2111.00	17.46	96528.82	0.85	1416.98	16.01	8276.89	34.28	28.86	29.59
8.	DRREDDY	1154.00	29.89	96322.06	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
9.	MANKIND	2328.55	47.09	96179.61	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
10.	AUROPHARMA	1653.30	25.62	95127.23	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
11.	GLENMARK	2427.00	38.10	68495.93	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	GUFICBIO	445.40	60.81	4466.58	0.02	22.31	70.72	260.82	16.58	12.56	17.87

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	195	215	202	195	203	204	208	205	227	230	231	252	261
	160	176	165	161	167	166	174	178	195	195	195	206	231
Operating Profit	35	39	36	34	36	39	34	27	32	36	36	46	30
OPM %	18.19%	18.32%	18.07%	17.55%	17.64%	18.91%	16.33%	12.99%	14.25%	15.54%	15.71%	18.21%	11.39%
	1	0	0	1	1	0	2	0	1	2	1	-1	0
Interest	4	4	3	4	5	5	5	8	9	10	8	9	9
Depreciation	4	4	4	4	4	4	5	8	8	8	8	8	8
Profit before Tax	28	31	30	27	28	29	26	11	16	21	21	28	30
Tax %	26.49%	25.01%	24.70%	26.07%	25.79%	25.60%	26.48%	26.07%	25.80%	27.23%	26.08%	25.52%	25.53%
Net Profit	21	23	22	20	21	22	19	8	12	15	16	21	22
	2.13	2.39	2.23	2.00	2.08	2.17	1.93	0.80	1.20	1.49	1.55	2.05	2.24

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	246	306	351	379	488	779	691	807	820	940	974
	223	267	305	327	404	631	556	659	683	790	827
Operating Profit	23	39	46	52	84	148	135	147	136	150	148
OPM %	9.35%	12.69%	13.11%	13.76%	17.21%	19.00%	19.50%	18.26%	16.64%	15.99%	15.16%
	1	4	4	6	4	3	3	2	4	3	2
Interest	6	9	10	14	14	5	8	17	25	37	37
Depreciation	4	4	5	14	16	19	22	17	21	31	31
Profit before Tax	14	30	35	30	58	127	107	116	94	85	99
Tax %	37.21%	44.99%	37.93%	24.69%	23.36%	24.44%	25.31%	25.53%	25.94%	26.13%	25.99%
Net Profit	9	16	22	23	44	96	80	86	70	63	74
EPS	1.17	2.12	2.82	2.34	4.56	9.89	8.22	8.59	6.97	6.30	—
Dividend Payout %	4.29%	2.36%	1.77%	2.14%	2.19%	1.01%	1.22%	1.16%	1.43%	1.59%	—

COMPOUNDED SALES GROWTH

10 Years:: 17%
5 Years:: 14%
3 Years:: 11%

COMPOUNDED PROFIT GROWTH

10 Years:: 24%
5 Years:: 7%
3 Years:: -7%

STOCK PRICE CAGR

10 Years:: 27%
5 Years:: 18%
3 Years:: 12%
1 Year:: 22%

RETURN ON EQUITY

10 Years:: 26%
5 Years:: 22%
3 Years:: 14%
Last Year:: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	8	8	8	10	10	10	10	10	10	10
	30	46	68	120	164	259	338	523	591	654
	61	84	102	128	63	67	333	313	310	379
Trade Payables	44	76	78	117	111	141	130	166	159	199
	33	21	55	33	72	45	50	81	100	99
Total Liabilities	175	235	310	407	419	521	860	1,093	1,170	1,342
	22	23	24	83	100	115	160	159	506	491
Capital Work in Progress	0	2	10	31	13	41	170	307	22	22
	0	0	0	0	0	0	1	2	3	3
	63	94	94	122	94	116	183	200	217	324
	1	2	1	1	1	1	1	330	315	297
Cash & Bank	6	7	8	16	13	27	47	13	28	74
	83	107	173	154	198	222	299	81	79	129
Total Assets	175	235	310	407	419	521	860	1,093	1,170	1,342

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	12	15	57	97	139	1	-7	123	44
Cash from Investing	-5	-9	-13	-43	-7	-95	-191	-102	-72	-31
Cash from Financing	7	14	8	-4	-79	-6	234	82	-37	32
	-1	1	-0	0	2	5	17	-27	14	45

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
PER SHARE
EPS (₹)	1.17	2.12	2.82	2.34	4.56	9.89	8.22	8.59	6.97	6.30
Book Value (₹)	4.83	6.96	9.68	13.34	17.89	27.76	35.88	53.11	59.96	66.23
Dividend per Share (₹)	0.05	0.05	0.05	0.05	0.10	0.10	0.10	0.10	0.10	0.10
Cash EPS (₹)	1.64	2.68	3.42	3.77	6.24	11.84	10.52	10.29	9.07	9.37
PROFITABILITY
Operating Margin %	9.37%	13.12%	13.92%	14.79%	16.90%	17.82%	17.14%	15.67%	12.39%	12.34%
Net Margin %	3.46%	5.19%	6.09%	5.80%	8.53%	11.30%	9.95%	9.16%	6.36%	5.18%
ROE %	25.31%	36.03%	33.89%	22.17%	29.22%	43.31%	25.84%	19.57%	12.34%	9.98%
ROCE %	24.26%	34.10%	29.65%	21.01%	30.05%	47.29%	23.23%	17.56%	13.51%	12.45%
	5.52%	8.04%	8.04%	6.33%	10.71%	20.37%	11.54%	8.82%	6.18%	5.03%
EFFICIENCY
Debtor Days	76	76	93	98	81	59	81	104	107	92
Inventory Days	79	90	95	101	76	45	68	75	69	81
Payable Days	164	170	174	227	184	125	168	160	191	187
	-8	-3	15	-28	-27	-20	-18	19	-15	-14
FINANCIAL HEALTH
Debt to Equity (x)	1.52x	1.47x	1.30x	0.90x	0.32x	0.23x	0.90x	0.60x	0.52x	0.58x
Interest Coverage (x)	3.27x	4.37x	4.48x	3.17x	5.23x	24.64x	13.98x	7.89x	4.85x	3.33x
	1.12x	1.18x	1.21x	1.14x	1.51x	1.72x	1.61x	1.61x	1.61x	1.55x
GROWTH
Revenue Growth %	21.42%	24.47%	14.79%	8.00%	28.74%	59.76%	-11.36%	16.80%	1.63%	14.72%
Operating Profit Growth %	19.88%	70.74%	20.44%	15.45%	51.37%	72.42%	-9.20%	8.93%	-6.33%	9.23%
Net Profit Growth %	23.16%	82.65%	33.17%	3.41%	94.96%	116.68%	-16.84%	8.07%	-18.81%	-9.70%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.48%	-18.81%	-9.71%
VALUATION
P/E (x)	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	32.96x	48.24x	43.60x
P/B (x)	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	5.33x	5.61x	4.15x
Dividend Yield %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.04%	0.03%	0.04%
	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	21.03x	26.11x	20.04x

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	72.50	72.51	72.51	72.51	72.52	72.50	72.50	72.50	72.50
	0.23	0.23	0.30	0.31	0.32	0.33	0.44	0.42	0.47
	2.38	2.51	2.99	3.39	3.38	3.66	3.74	3.83	3.67
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	24.88	24.74	24.21	23.79	23.78	23.51	23.32	23.25	23.36

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-04

Shareholders meeting

2026-09-04 - Gufic Biosciences Limited has informed the Exchange regarding Proceedings of 42nd Annual General Meeting held on September 04, 2026

2026-09-02

General Updates

2026-09-02 - Gufic Biosciences Limited has informed the Exchange about Promotion and Change in Designation of Senior Management Personnel

2026-08-21

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-21 - Gufic Biosciences Limited has informed the Exchange about Transcript

2026-08-18

Copy of Newspaper Publication

2026-08-18 - Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of Physical Shares

2026-08-17

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-17 - Gufic Biosciences Limited has informed the Exchange about Link of Recording

2026-08-15

Copy of Newspaper Publication

2026-08-15 - Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026

2026-08-14

General Updates

2026-08-14 - Gufic Biosciences Limited has submitted to the Exchange the Investor Presentation for the quarter ended June 30, 2026

2026-08-14

Acquisition

2026-08-14 - Gufic Biosciences Limited has informed the Exchange about Acquisition

2026-08-14

Outcome of Board Meeting

2026-08-14 - Gufic Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. and information pertaining approval for Incorporation of Subsidiary in the Philippines and Investment by way of Subscription to its Equity Share Capital

News

Recent coverage and analyst commentary for GUFICBIO

Loading news…

🤖

AI Stock Analyst

Gufic Biosciences Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account